VANCOUVER, BC / ACCESSWIRE / April 24, 2024 / Ondine Biomedical (LON:OBI), a leading provider of light-activated antimicrobial technology to treat and prevent hospital infections, provides an update on its recent developments, strategic priorities and 2024 corporate plans.
VANCOUVER, BC / ACCESSWIRE / April 22, 2024 / Ondine Biomedical Inc. (LSE:OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that Mater Hospital, North Sydney, a private hospital in New South Wales, has become the first Australian hospital to start using its light-activated antimicrobial Steriwave® technology to prevent the spread of hospital-acquired infections (HAIs). Mater Hospital, located in North Sydney and founded in 1906, is part of St. Vincent's Health Australia Group, Australia's largest not-for-profit provider of health and aged care services.
Ondine Biomedical Announces First commercial adoption of Steriwave by the NHS
VANCOUVER, BC / ACCESSWIRE / March 21, 2024 / Ondine Biomedical Inc. (LON:OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments to prevent and treat healthcare-associated infections (HAIs), announces that a UK-based study demonstrated a significant reduction in antibiotic use following sinus surgeries where Steriwave® was used for pre-surgical nasal decolonization.
Ondine Biomedical Inc. Announces Appointment of new Chief Financial Officer
VANCOUVER, BC / ACCESSWIRE / December 13, 2023 / Following its successful fundraising of C$4.91 million (US$3.62), Canadian life sciences company Ondine Biomedical Inc. (AIM:OBI) will continue accelerating commercialisation of its proven nasal photodisinfection technology. This cutting-edge technology replaces topical antibiotics for the prevention of healthcare-associated infections (HAIs) and kills all types of pathogens - bacteria, viruses and fungi - without causing antimicrobial resistance.
Ondine Biomedical’s photodisinfection recommended as standard of care
VANCOUVER, BC / ACCESSWIRE / September 29, 2023 / Burnaby Hospital, a large community hospital in British Columbia, has initiated use of Ondine Biomedical's (OBI:LON) Steriwave® nasal photodisinfection prior to orthopedic surgery to further reduce the incidence of post-surgical infections. Burnaby Hospital, which is affiliated with the University of British Columbia and an integral part of the Fraser Health Authority, has been focused on further reducing infections and optimizing patient outcomes following orthopedic surgery.
VANCOUVER, BC / ACCESSWIRE / September 14, 2023 / Canadian life sciences company Ondine Biomedical Inc. (LON:OBI) is presenting new research at the 2023 International Consortium on Prevention & Infection Control (ICPIC) in Geneva, demonstrating high efficacy of its patented photodisinfection technology against extensively drug-resistant (XDR) bacteria. Ondine is the global leader in developing photodisinfection-based therapies for the prevention of healthcare-associated infections.
First NHS pilot of Ondine Biomedical’s nasal photodisinfection for the prevention of post-surgical infections starts at Mid Yorkshire Teaching NHS Trust